HS-10502 + HS-20093

HS-10502 + HS-20093 is an investigational combination therapy for advanced solid tumors. HS-10502 is a PARP1-specific selective inhibitor, administered orally, designed to inhibit the activity of poly(ADP-ribose) polymerase 1 (PARP1), a key enzyme involved in DNA repair. By inhibiting PARP1, it aims to enhance cancer cell death, particularly in tumors with defective DNA repair mechanisms[1][2][5]. HS-20093 is a novel B7-H3-targeted antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. It targets the B7-H3 (CD276) protein expressed on tumor cells and delivers the cytotoxic payload directly into these cells, leading to their destruction[3][4][6]. The combination is being evaluated in phase I clinical trials for safety, tolerability, pharmacokinetics, and efficacy across multiple advanced solid tumor types including recurrent ovarian cancer, HER2-negative advanced breast cancer, triple-negative breast cancer (TNBC), advanced prostate cancer, and advanced gastric cancer[2][5].